Serum insulin-like growth factor-I and breast cancer

Toniolo, Paolo; Bruning, P.F.; Akhmedkhanov, Arslan; Bonfrèr, Johannes M.G.; Koenig, Karen L.; Lukanova, Annekatrin; Shore, Roy E.; Zeleniuch‐Jacquotte, Anne

doi:10.1002/1097-0215(20001201)88:5<828::aid-ijc22>3.0.co;2-8

Cited by 301 publications

(235 citation statements)

References 21 publications

(28 reference statements)

Supporting

Mentioning

215

Contrasting

Unclassified

Order By: Relevance

“…This is broadly consistent with previous prospective studies that have found IGF-I, as absolute concentrations or relative to IGFBP-3, to be predictive (Hankinson et al, 1998;Toniolo et al, 2000;Krajcik et al, 2002;Muti et al, 2002), although one study found no association between serum IGF-I levels and risk in women who were under the age of 50 years at the time of diagnosis . The finding that serum IGF-I was not associated with breast cancer risk in postmenopausal women is consistent with data from other prospective studies (Hankinson et al, 1998;Kaaks et al, 2002;Krajcik et al, 2002;Toniolo et al, 2000;Keinan-Boker et al, 2003;Gr nbaek et al, 2004).…”

Section: Discussionsupporting

confidence: 90%

“…This variation may be important because epidemiological evidence suggests that elevated levels of serum IGF-I, as absolute concentrations or relative to IGFBP-3, may be associated with an increased risk of breast cancer in premenopausal women (Peyrat et al, 1993;Bruning et al, 1995;Bohlke et al, 1998;Hankinson et al, 1998;Petridou et al, 2000;Toniolo et al, 2000;Kaaks et al, 2002;Krajcik et al, 2002;Muti et al, 2002;Yu et al, 2002;Keinan-Boker et al, 2003). There are limited data on the association between serum IGF-II concentration and breast cancer risk (Holdaway et al, 1999;Li et al, 2001;Yu et al, 2002;Gr nbaek et al, 2004).…”

mentioning

confidence: 99%

See 1 more Smart Citation

A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk

et al. 2005

View full text Add to dashboard Cite

The associations between serum concentrations of insulin-like growth factor-I (IGF-I), IGF-II and IGF-binding proteins (IGFBP)-3 and risk of breast cancer were investigated in a nested case -control study involving 117 cases (70 premenopausal and 47 postmenopausal at blood collection) and 350 matched controls within a cohort of women from the island of Guernsey, UK. Women using exogenous hormones at the time of blood collection were excluded. Premenopausal women in the top vs bottom third of serum IGF-I concentration had a nonsignificantly increased risk for breast cancer after adjustment for IGFBP-3 (odds ratio (OR) 1.71; 95% confidence interval (CI): 0.74 -3.95; test for linear trend, P ¼ 0.21). Serum IGFBP-3 was associated with a reduction in risk in premenopausal women after adjustment for IGF-I (top third vs the bottom third: OR 0.49; 95% CI: 0.21 -1.12, P for trend ¼ 0.07). Neither IGF-I nor IGFBP-3 was associated with risk in postmenopausal women and serum IGF-II concentration was not associated with risk in pre-or postmenopausal women. These data are compatible with the hypothesis that premenopausal women with a relatively high circulating concentration of IGF-I and low IGFBP-3 are at an increased risk of developing breast cancer. It is well established that insulin-like growth factor-I (IGF-I) and IGF-II can stimulate cell proliferation and inhibit cell death in many tissue types (Pollak, 2000) including normal and malignant breast cancer cells (Sachdev and Yee, 2001). The bioavailability of circulating IGF ligands is complex; at least six IGF-binding proteins (IGFBPs) have been identified, the most abundant of which is IGFBP-3. This binds approximately 75 -90% of circulating IGF-I and IGF-II and may be the most important determinant of IGF bioavailability (Jones and Clemmons, 1995).There is considerable between-person variation in the circulating concentrations of IGF-I, IGF-II and their binding proteins, believed to be due to genetic and environmental factors (Jones and Clemmons, 1995;Harrela et al, 1996). This variation may be important because epidemiological evidence suggests that elevated levels of serum IGF-I, as absolute concentrations or relative to IGFBP-3, may be associated with an increased risk of breast cancer in premenopausal women (Peyrat et al, 1993;Bruning et al, 1995;Bohlke et al, 1998;Hankinson et al, 1998;Petridou et al, 2000;Toniolo et al, 2000;Kaaks et al, 2002;Krajcik et al, 2002;Muti et al, 2002;Yu et al, 2002;Keinan-Boker et al, 2003). There are limited data on the association between serum IGF-II concentration and breast cancer risk (Holdaway et al, 1999;Li et al, 2001;Yu et al, 2002;Gr nbaek et al, 2004).The aim of this study is to examine the associations between serum concentrations of IGF-I, IGF-II and IGFBP-3 and subsequent breast cancer risk in a case -control study nested within a cohort of women on the island of Guernsey. MATERIALS AND METHODS The Guernsey cohortBetween 1977 and 1991, 6127 women aged 35 years or older who lived on the British island of Guernsey were re...

show abstract

Section: Discussionsupporting

confidence: 90%

mentioning

confidence: 99%

A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk

et al. 2005

View full text Add to dashboard Cite

show abstract

“…However, it has also been shown to promote tumor growth [1]. Prospective cohort studies have observed that subjects with elevated levels of IGF-I are at increased risk of developing several types of cancer, including prostate, premenopausal breast, and colorectal cancer [2][3][4][5][6][7][8]. IGF action is determined by the availability of IGF-I to interact with the IGF-I receptor, and is dependent not only on absolute IGF-I concentrations, but also on the relative concentrations of several IGF binding proteins IGFBPs [9].…”

Section: Introductionmentioning

confidence: 99%

“…A high concentration of IGFBP-3, the main IGF binding protein in the circulation, is thought to reduce IGF-I action. However, studies on the association between plasma IGFBP-3 levels and cancer risk remain inconclusive [2,3,[5][6][7][8]. Only a small fraction of IGF-I in the circulation is bound to IGFBP-1 and IGFBP-2, in complexes which allow transport of IGF-I out of the bloodstream, possibly resulting in increased levels of IGF-I in tissues.…”

Section: Introductionmentioning

confidence: 99%

Dietary Determinants of Circulating Insulin-like Growth Factor (IGF)-I and IGF Binding Proteins 1, -2 and -3 in Women in the Netherlands

Vrieling

Voskuil

Mesquita

et al. 2004

Cancer Causes Control

View full text Add to dashboard Cite

Objective: Epidemiological studies suggest that individuals with elevated plasma concentrations of insulin-like growth factor (IGF-I) are at increased risk of developing cancer. We assessed whether dietary intake of total energy, protein, alcohol, phytoestrogens and related foods, and tomatoes and lycopene was associated with plasma levels of IGF-I and IGF binding proteins (IGFBPs) in Dutch women. Methods: A cross-sectional study was conducted in 224 premenopausal and 162 postmenopausal women, aged 49-69, participating in the Prospect-EPIC study in the Netherlands. Diet was assessed using a food frequency questionnaire. Results: In postmenopausal women, higher alcohol intake was associated with lower plasma IGFBP-1 concentrations (alcohol 1.4 to 20 g/day: 20% decrease in IGFBP-1; p ¼ 0.04), and higher intake of plant lignans was associated with higher IGFBP-1 concentrations (plant lignans 0 to 1 mg/day: 59% increase in IGFBP-1; p ¼ 0.02). Higher soy intake was associated with higher plasma IGFBP-2 concentrations in premenopausal women (soy 0 to 2.5 g/day: 3% increase in IGFBP-2; p ¼ 0.04). No independent associations of dietary factors with IGF-I or IGFBP-3 concentrations were observed. However, in premenopausal women alcohol intake was inversely associated with IGF-I and positively associated with IGFBP-3 after mutual adjustment. Conclusions: In this study population, with limited variation in dietary intake, total energy, protein, phytoestrogens and lycopene were not associated with IGF-I and IGFBP-3. Alcohol was inversely, and some measures of phytoestrogen intake were positively associated with plasma IGFBP-1 or -2 concentrations. The roles of IGFBP-1 and -2 in relation to IGF-I bioactivity and cancer deserve further investigation.

show abstract

“…A number of epidemiologic studies have shown a direct association between circulating IGF-I levels and breast cancer risk, especially in young women (Peyrat et al, 1993;Bruning et al, 1995;Bohlke et al, 1998;Hankinson et al, 1998;Toniolo et al, 2000;Muti et al, 2002;Yu et al, 2002). Elevated circulating IGF-I also has been found to be a potential cancer risk factor for cancers of other organs, such as the prostate (Mantzoros et al, 1997;Chan et al, 1998;Wolk et al, 1998;Stattin et al, 2000) and the colorectum (Ma et al, 1999;Giovannucci et al, 2000;Kaaks et al, 2000;Palmqvist et al, 2002).…”

mentioning

confidence: 99%

Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study

et al. 2006

View full text Add to dashboard Cite

Insulin-like growth factor I (IGF-I) stimulates cell proliferation and can enhance the development of tumours in different organs. Epidemiological studies have shown that an elevated level of circulating IGF-I is associated with increased risk of breast cancer, as well as of other cancers. Most of circulating IGF-I is bound to an acid-labile subunit and to one of six insulin-like growth factor binding proteins (IGFBPs), among which the most important are IGFBP-3 and IGFBP-1. Polymorphisms of the IGF1 gene and of genes encoding for the major IGF-I carriers may predict circulating levels of IGF-I and have an impact on cancer risk. We tested this hypothesis with a case -control study of 807 breast cancer patients and 1588 matched control subjects, nested within the European Prospective Investigation into Cancer and Nutrition. We genotyped 23 common single nucleotide polymorphisms in IGF1, IGFBP1, IGFBP3 and IGFALS, and measured serum levels of IGF-I and IGFBP-3 in samples of cases and controls. We found a weak but significant association of polymorphisms at the 5 0 end of the IGF1 gene with breast cancer risk, particularly among women younger than 55 years, and a strong association of polymorphisms located in the 5 0 end of IGFBP3 with circulating levels of IGFBP-3, which confirms previous findings. Common genetic variation in these candidate genes does not play a major role in altering breast cancer risk in Caucasians.

show abstract

Serum insulin-like growth factor-I and breast cancer

Cited by 301 publications

References 21 publications

A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk

A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk

Dietary Determinants of Circulating Insulin-like Growth Factor (IGF)-I and IGF Binding Proteins 1, -2 and -3 in Women in the Netherlands

Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study

Contact Info

Product

Resources

About